You just read:

Mitsubishi Pharma Europe's Anticoagulant Exembol® (argatroban) Receives Acceptance from the Scottish Medicines Consortium (SMC) as Treatment for Patients with Heparin-induced Thrombocytopenia Type II (HIT)

News provided by

Mitsubishi Pharma Europe Ltd

22 Aug, 2013, 18:24 BST